CONTACT
CAPTCHA
Change the CAPTCHA code

COURSE
sign up

Advances in the Treatment of Renal Cell Carcinoma

This activity is designed to educate health care professionals about the latest advances in treatment for renal cell carcinoma.

show all
DETAILS
Category: Pharmacology Nursing Internal Medicine
Views: 73
Number: 4017
visibility 21 days to the end of the display (June 17 2018)
price:
$0
TERMS
Start
End
City
term set individually
New York, NY
z 100 spots
Sign up to reserve a place. Within 48 hours the presenter will contact you.
SELLER
Name: Applied Clinical Education
Phone: 201-218-9656
DESCRIPTION

Advancements in the Treatment of Renal Cell Carcinoma
Module 1: Background and VEGF-Targeted Therapy
Module 2: Adjuvant and Combination Therapy

Release Date: November 20, 2017
Expiration Date: November 20, 2018

Faculty

  • Ana M. Molina, MD (Module 1)

Assistant Professor of Medicine
Weill Cornell Medicine
NewYork-Presbytarian Hospital
New York, New York

  • Lauren C. Harshman, MD (Module 2)

Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Goal

This activity is designed to educate health care professionals about the latest advances in treatment for renal cell carcinoma.

Learning Objectives

At the completion of this activity, participants should be better prepared to:

  • Review the demographics, underlying disease mechanisms, and evolution of treatment in RCC
  • Analyze current and emerging clinical efficacy and safety data on the use of VEGF-targeted and immunotherapeutic agents in advanced RCC
  • Develop individualized first-line and subsequent therapeutic plans for patients with advanced RCC based on current guidelines and evidence
  • Discuss the management of AEs encountered during treatment for advanced RCC, including potential new toxicity profiles with novel agents and combinations

Intended Audience

  • Medical oncologists
  • Hematologists/oncologists
  • Oncology nurses
  • Urologists
  • Pharmacists

Estimated Time for Completion

30 minutes

Course Format

Web-based

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Applied Clinical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Global Education Group designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

To receive CME credit, participants should read the monograph and complete the pre-test, posttest, and activity evaluation. CME certificates will be made available immediately upon successful completion.

Fees

Free

Disclosure of Conflicts of Interest

Global Education Group requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are vetted thoroughly by Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

  • Module 1: Ana Molina, MD: Exelixis, Inc., Novartis Pharmaceuticals (consultant/independent contractor); International Kidney Cancer Symposium (honoraria)
  • Module 2: Lauren C. Harshman, MD: Genentech, Kew Group, Medivation/Astellas, Pfizer, Theragene (consultant/independent contractor); Bayer, Bristol-Myers Squibb, Dendreon/Valient, Genentech, Jannsen, Medivation/Astellas, Merck, Pfizer, Sotio, Takeda (grant/research support)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

  • Jennifer Kulpa: Nothing to disclose
  • Dru Dace, PhD: Nothing to disclose
  • Andrea Funk: Nothing to disclose
  • Ashley Marostica, Lindsay Knight: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Applied Clinical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer

Participants have an implied responsibility to use newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or courses of diagnosis or treatment discussed should not be used by clinicians without evaluation of patient conditions, contraindications, applicable manufacturer’s product information, and the recommendations of other authorities.

Accreditor Contact Information

For information about the accreditation of this program, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

System Requirements

  • Operating System: Windows or Macintosh
  • Media Viewing Requirements: Flash Player or Adobe Reader
  • Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
  • A good Internet connection

Module 1: Background and VEGF-Targeted Therapy
Module 2: Adjuvant and Combination Therapy

REVIEWS
MED COURSES
Terms Privacy Policy Advertise Contact us